InflaRx N.V.
InflaRx N.V. applies proprietary anti-C5a and anti-C5aR technologies to discover, develop, and commercialize inhibitors of the complement activation factor C5a and its receptor C5aR.
Classification
Profile
Funding
Funding details not yet available.
Develops highly potent and specific inhibitors of complement activation factor C5a and its receptor C5aR using proprietary anti-C5a and anti-C5aR technologies.
Patients suffering from complement-mediated diseases; pharmaceutical partners for co-development or licensing of proprietary technologies.
Likely licensing of proprietary technology and future sales of commercialized drug candidates, potentially supported by regulatory authorizations.
Direct engagement for regulatory approvals (e.g., FDA EUA) and strategic partnerships for drug development and commercialization.
Regulatory bodies like the U.S. FDA for Emergency Use Authorization; potential pharmaceutical partners for development and commercialization.
Primary costs driven by research and development of proprietary technologies, clinical trials, and regulatory compliance efforts.
Proprietary anti-C5a and anti-C5aR technologies, intellectual property, and regulatory approvals such as the FDA Emergency Use Authorization.
Discovery, development, and commercialization of complement inhibitors; securing regulatory authorizations and managing clinical trials.
Regulatory compliance and partnership-driven relationships; likely B2B focus for technology licensing and drug development collaboration.
Competes in the complement inhibition space with specific focus on C5a and C5aR; differentiates via proprietary technology and FDA EUA.
Unmet needs in treating complement-mediated diseases; lack of highly specific and potent inhibitors for C5a and C5aR pathways.
- Accelerate out-licensing of Izicopan - Initiate a targeted “partner-first” business-development sprint with top-10 pharma firms, offering
Map a 12-month licensing roadmap - Identify top 5 potential partners, set up joint-development workshops, and prepare data-room packages · Finalize orphan-drug applications for INF904 and Izicopan in EU and US to lock in exclusivity benefits before Phase-III read-outs · Launch a targeted investor-communication campaign highlighting the cost-cutting
- Pipeline depth is solid - The company already has an FDA-authorized emergency-use product (Gohibic) and multiple candidates at Phase-II/I
Team details not yet available.
No investors recorded yet.